Keymed Biosciences Inc
Company Profile
Business description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact
No. 18 BioTown Middle Road
Building D2
Tianfu International BioTown, Chengdu
Sichuan610219
CHNT: +86 2888610620
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,625
Stocks News & Analysis
stocks
Strong guidance from undervalued ASX share
stocks
TSMC earnings: Refining guidance and expansion plans amid strong AI demand
stocks
Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,167.40 | 5.30 | 0.06% |
| CAC 40 | 8,425.13 | 0.00 | 0.00% |
| DAX 40 | 24,702.24 | 547.77 | 2.27% |
| Dow JONES (US) | 49,447.43 | 868.71 | 1.79% |
| FTSE 100 | 10,667.63 | 77.64 | 0.73% |
| HKSE | 26,343.18 | 182.85 | 0.70% |
| NASDAQ | 24,468.48 | 365.78 | 1.52% |
| Nikkei 225 | 59,045.45 | 569.55 | 0.97% |
| NZX 50 Index | 12,898.34 | 7.33 | -0.06% |
| S&P 500 | 7,126.06 | 84.78 | 1.20% |
| S&P/ASX 200 | 8,943.90 | 4.20 | 0.05% |
| SSE Composite Index | 4,077.66 | 26.24 | 0.65% |